280 related articles for article (PubMed ID: 24399877)
1. First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel.
Gupta N; Hatoum H; Dy GK
Int J Nanomedicine; 2014; 9():209-21. PubMed ID: 24399877
[TBL] [Abstract][Full Text] [Related]
2. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.
Socinski MA; Bondarenko I; Karaseva NA; Makhson AM; Vynnychenko I; Okamoto I; Hon JK; Hirsh V; Bhar P; Zhang H; Iglesias JL; Renschler MF
J Clin Oncol; 2012 Jun; 30(17):2055-62. PubMed ID: 22547591
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer.
Socinski MA; Okamoto I; Hon JK; Hirsh V; Dakhil SR; Page RD; Orsini J; Yamamoto N; Zhang H; Renschler MF
Ann Oncol; 2013 Sep; 24(9):2390-6. PubMed ID: 23842283
[TBL] [Abstract][Full Text] [Related]
4. Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients.
Bertino EM; Williams TM; Nana-Sinkam SP; Shilo K; Chatterjee M; Mo X; Rahmani M; Phillips GS; Villalona-Calero MA; Otterson GA
Clin Lung Cancer; 2015 Nov; 16(6):466-74. PubMed ID: 26123189
[TBL] [Abstract][Full Text] [Related]
5. Albumin-Bound Paclitaxel: A Review in Non-Small Cell Lung Cancer.
Blair HA; Deeks ED
Drugs; 2015 Nov; 75(17):2017-24. PubMed ID: 26541764
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L
J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticle albumin bound-paclitaxel for treatment of advanced non-small cell lung cancer: an evaluation of the clinical evidence.
Adrianzen Herrera D; Ashai N; Perez-Soler R; Cheng H
Expert Opin Pharmacother; 2019 Jan; 20(1):95-102. PubMed ID: 30439289
[TBL] [Abstract][Full Text] [Related]
8. A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer.
Socinski MA; Manikhas GM; Stroyakovsky DL; Makhson AN; Cheporov SV; Orlov SV; Yablonsky PK; Bhar P; Iglesias J
J Thorac Oncol; 2010 Jun; 5(6):852-61. PubMed ID: 20521351
[TBL] [Abstract][Full Text] [Related]
9. nab-paclitaxel for the management of patients with advanced non-small-cell lung cancer.
Hirsh V
Expert Rev Anticancer Ther; 2014 Feb; 14(2):129-41. PubMed ID: 24467217
[TBL] [Abstract][Full Text] [Related]
10. Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301.
Miyauchi E; Inoue A; Usui K; Sugawara S; Maemondo M; Saito H; Fujita Y; Kato T; Suzuki T; Harada T; Watanabe H; Nakagawa T; Ichinose M
Oncologist; 2017 Jun; 22(6):640-e59. PubMed ID: 28526722
[TBL] [Abstract][Full Text] [Related]
11. Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: analysis of safety and efficacy in patients with renal impairment.
Langer CJ; Hirsh V; Ko A; Renschler MF; Socinski MA
Clin Lung Cancer; 2015 Mar; 16(2):112-20. PubMed ID: 25572008
[TBL] [Abstract][Full Text] [Related]
12. Retrospective analysis of the effectiveness and tolerability of nab-paclitaxel in Chinese elderly patients with advanced non-small-cell lung carcinoma.
Wang S; Liang Q; Chi Y; Zhuo M; An T; Duan J; Wang Z; Wang Y; Zhong J; Yang X; Chen H; Wang J; Zhao J
Thorac Cancer; 2020 May; 11(5):1149-1159. PubMed ID: 32162417
[TBL] [Abstract][Full Text] [Related]
13. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.
Shitara K; Takashima A; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Makari Y; Amagai K; Ueda S; Yoshida K; Shimodaira H; Nishina T; Tsuda M; Kurokawa Y; Tamura T; Sasaki Y; Morita S; Koizumi W
Lancet Gastroenterol Hepatol; 2017 Apr; 2(4):277-287. PubMed ID: 28404157
[TBL] [Abstract][Full Text] [Related]
14. ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC).
Morgensztern D; Cobo M; Ponce Aix S; Postmus PE; Lewanski CR; Bennouna J; Fischer JR; Juan-Vidal O; Stewart DJ; Fasola G; Ardizzoni A; Bhore R; Wolfsteiner M; Talbot DC; Jin Ong T; Govindan R; On Behalf Of The Abound L Investigators
Cancer; 2018 Dec; 124(24):4667-4675. PubMed ID: 30383906
[TBL] [Abstract][Full Text] [Related]
15. Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Diabetes.
Hirsh V; Ko A; Pilot R; Renschler MF; Socinski MA
Clin Lung Cancer; 2016 Sep; 17(5):367-374. PubMed ID: 27230605
[TBL] [Abstract][Full Text] [Related]
16. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer.
Green MR; Manikhas GM; Orlov S; Afanasyev B; Makhson AM; Bhar P; Hawkins MJ
Ann Oncol; 2006 Aug; 17(8):1263-8. PubMed ID: 16740598
[TBL] [Abstract][Full Text] [Related]
17. Safety and pharmacokinetic study of nab-paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer.
Okamoto I; Yamamoto N; Kubota K; Ohe Y; Nogami N; Murakami H; Yamaya H; Ono K; Nakagawa K
Invest New Drugs; 2012 Jun; 30(3):1132-7. PubMed ID: 21537886
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer.
Villaruz LC; Cobo M; Syrigos K; Mavroudis D; Zhang W; Kim JS; Socinski MA
Lung Cancer; 2019 Oct; 136():52-56. PubMed ID: 31445354
[TBL] [Abstract][Full Text] [Related]
19. Patient-reported neuropathy and taxane-associated symptoms in a phase 3 trial of nab-paclitaxel plus carboplatin versus solvent-based paclitaxel plus carboplatin for advanced non-small-cell lung cancer.
Hirsh V; Okamoto I; Hon JK; Page RD; Orsini J; Sakai H; Zhang H; Renschler MF; Socinski MA
J Thorac Oncol; 2014 Jan; 9(1):83-90. PubMed ID: 24346096
[TBL] [Abstract][Full Text] [Related]
20. nab-Paclitaxel mechanisms of action and delivery.
Yardley DA
J Control Release; 2013 Sep; 170(3):365-72. PubMed ID: 23770008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
